Evidence mapPaperPMID 42352263Full record

ReviewBiomolecules2026

Glycolysis: The Bridge Between Cellular Interaction and Alzheimer's Disease.

Qian Lei, Yinghan He, Bo Fang

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qian LeiDepartment of Anesthesiology, The First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang 110001, China.
Yinghan HeDepartment of Anesthesiology, The First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang 110001, China.
Bo FangDepartment of Anesthesiology, The First Hospital of China Medical University, NO. 155, North Nanjing Street, Heping District, Shenyang 110001, China.ORCID 0000-0002-4812-6919

Funding

Liaoning Red Cross Foundation 2900025016National Natural Science Foundation of China 81971152The Health Commission of Liaoning Province XLYC2412063
6 · The paper itself

Abstract

The pathological progression of Alzheimer's disease (AD) involves not only intrinsic neuronal lesions but is also closely associated with dysregulation of intercellular communication within the neuroimmune microenvironment. Glycolysis, as a central pathway in cellular energy metabolism, exhibits significant abnormalities in AD, and changes in its activity may further influence disease progression by modulating interactions between neurons. This article aims to systematically elucidate how glycolysis, as a key component of metabolic regulation, participates in the regulation of cellular interactions during the progression of AD, and to explore its potential mechanisms and therapeutic implications. Firstly, it systematically reviews the key changes in interactions between cells in AD, including microglia, astrocytes, oligodendrocytes, and neurons, and their roles in neuroinflammation, synaptic loss, and amyloid deposition. Secondly, by analysing alterations in the glycolytic metabolic profiles of various neuronal cell types in AD, we explore in depth how glycolysis regulates cellular signalling, inflammatory responses, and cellular function, thereby influencing cell-cell interactions. Lastly, by combining current research on the control of the glycolytic pathway in AD with possible therapeutic methods, we propose a novel way to stop the progression of the disease by focusing on cell interactions through mediating glycolysis. By tracing the causal chain in AD through which glycolysis acts as a bridge via altered cell-cell interactions, this paper aims to provide a theoretical basis for the development of disease-modifying therapies based on metabolic reprogramming.

Indexed as

Alzheimer DiseaseCell CommunicationGlycolysisAnimalsAstrocytesEnergy MetabolismHumansMicrogliaNeuronsAlzheimer’s disease (AD)cellular interactionsexosomesglycolysistunneling nanotubes (TNTs)

Identifiers

PMID42352263
PMCPMC13296872

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.